WO1997002920A1 - Installation pour la fermeture automatisee et hermetique de boitiers - Google Patents

Installation pour la fermeture automatisee et hermetique de boitiers Download PDF

Info

Publication number
WO1997002920A1
WO1997002920A1 PCT/AT1996/000121 AT9600121W WO9702920A1 WO 1997002920 A1 WO1997002920 A1 WO 1997002920A1 AT 9600121 W AT9600121 W AT 9600121W WO 9702920 A1 WO9702920 A1 WO 9702920A1
Authority
WO
WIPO (PCT)
Prior art keywords
welding
chamber
welding chamber
plant according
electrode
Prior art date
Application number
PCT/AT1996/000121
Other languages
German (de)
English (en)
Inventor
Gerhard Zeindl
Frowald Angerer
Karl Schweitzer
Original Assignee
Datacon Schweitzer & Zeindl Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Datacon Schweitzer & Zeindl Gmbh filed Critical Datacon Schweitzer & Zeindl Gmbh
Priority to AU62930/96A priority Critical patent/AU6293096A/en
Priority to EP96921811A priority patent/EP0837751A1/fr
Publication of WO1997002920A1 publication Critical patent/WO1997002920A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B23—MACHINE TOOLS; METAL-WORKING NOT OTHERWISE PROVIDED FOR
    • B23K—SOLDERING OR UNSOLDERING; WELDING; CLADDING OR PLATING BY SOLDERING OR WELDING; CUTTING BY APPLYING HEAT LOCALLY, e.g. FLAME CUTTING; WORKING BY LASER BEAM
    • B23K11/00—Resistance welding; Severing by resistance heating
    • B23K11/002—Resistance welding; Severing by resistance heating specially adapted for particular articles or work
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B23—MACHINE TOOLS; METAL-WORKING NOT OTHERWISE PROVIDED FOR
    • B23K—SOLDERING OR UNSOLDERING; WELDING; CLADDING OR PLATING BY SOLDERING OR WELDING; CUTTING BY APPLYING HEAT LOCALLY, e.g. FLAME CUTTING; WORKING BY LASER BEAM
    • B23K2101/00—Articles made by soldering, welding or cutting
    • B23K2101/36—Electric or electronic devices
    • B23K2101/40—Semiconductor devices

Definitions

  • the invention relates to a system for the automated, hermetic sealing of housings, preferably metal housings, in which electronic components, in particular in an oxygen and steam-free atmosphere, are arranged, optionally with a welding chamber operated with nitrogen overpressure or underpressure, which has at least one with two to one another Movable electrodes trained welding head and corresponding feed and discharge devices for the housing to and from the welding head.
  • Such systems are mainly used in the manufacture of electronic components.
  • each of these drives also has disadvantages.
  • the pneumatic drive is flexible in the opening travel and pressure setting, the opening and closing times are extremely long.
  • the eccentric drive has a high closing speed, but is extremely inflexible in its movement.
  • the object of the invention is to provide a system which avoids the disadvantages mentioned above and which also ensures a higher quality in production.
  • a quality standard for such systems is that a hermetic sealing of the housing is possible, the interior of the housing should be absolutely free of oxygen and water vapor.
  • the system according to the invention cited at the beginning is characterized in that the welding chamber can be evacuated and the welding head has at least one electrode which can be moved via a servo drive.
  • the servo drive allows a high cycle frequency in the production line.
  • the welding chamber is sealed and evacuated, with this evacuation being carried out in an average of 15 minutes. All atmospheric gases are extracted and then the welding chamber is filled with inert gas. The system is ready for operation again in no time.
  • the welding chamber is connected to a gas drying circuit.
  • This gas drying circuit essentially consists of two drying cartridges which contain a gas drying agent and each drying cartridge is connected separately to the welding chamber. A cartridge dries the inert gas from the welding chamber in operation. In the other cartridge, the moisture absorbed is extracted from the drying agent via vacuum and temperature. Through this alternating procedure, the operability of the system is always guaranteed.
  • the welding space located in the welding head which surrounds the housing provided for welding, can be evacuated when the electrodes are closed. In order to obtain an even higher freedom from gas in the interior of the housing to be closed, evacuation is carried out shortly before welding in the welding head with the electrodes closed. Vacuum values of the order of 10 torr can be achieved.
  • At least one electrode of the welding head has a channel for evacuation and a sealing ring for sealing off the second electrode.
  • the procedure in the welding head is as follows: After inserting the housing into an electrode, the second electrode is closed until the O-ring seals. After a few seconds of evacuation, the electrodes are closed on the welding position. After the welding process, the electrodes are opened and the housing is removed using the ejector.
  • the simple evacuation facility has resulted in a significant improvement in quality.
  • the drying chamber is preceded by a drying oven and optionally a subsequent prechamber for the intermediate storage of the housing to be closed, the
  • Entry opening into the welding chamber can be closed by a lock flap.
  • the lock flap ensures that the welding chamber operates properly.
  • the housings coming out of the drying oven must no longer come into contact with the environmental atmosphere. This means that housings that are delivered from the drying oven can also be used for service work in the
  • Welding chamber are upstream. In addition, only the welding chamber has to be evacuated through the lock flap after the service work.
  • an outlet lock chamber which can be both evacuated and flushed with inert gas, and the inlet and outlet openings of which each have a lock flap are reproduced in the welding chamber is lockable.
  • the exit lock chamber 8 with its two lock flaps is of particular advantage.
  • helium gas is added to the nitrogen for operating the welding chamber.
  • This added helium gas is an indicator of the welding quality. If a housing leaks after the welding process, the gas flows out and is detected by a sensor.
  • a quick method for quality control is preferably provided for random samples.
  • the servo drive consists of an electronically controlled electric motor that drives a spindle, preferably a ball screw. This simple drive for closing and opening the electrode has proven its worth. Above all through the adjustability of the
  • the electrode is preferably supported vertically by a spring assembly. This resilient
  • the purpose of the support is that during the actual welding process, the flanging of the housing becomes practically zero, and the electrode has to be moved to a minimum in order to enable an optimal closure.
  • the sealing necessary for the evacuation takes place on the rotating spindle part.
  • Such a seal is to be carried out with conventional machine components, a high level of operational safety being guaranteed.
  • FIG. 1 shows the schematic structure of the Complete system
  • FIG. 2 the welding head with the servo drive
  • FIG. 3 an evacuable electrode
  • FIG. 4 the movement sequence during welding.
  • the system for closing the metal housing consists of several chambers.
  • the core of this system is the welding chamber 1, in which the welding head 2 is also arranged
  • the welding chamber 1 Since electronic components are provided in the metal housings, these metal housings must be sealed in an atmosphere free of oxygen and water vapor. In order for this atmosphere to exist, the welding chamber 1 is operated in operation with a nitrogen overpressure, possibly also with a negative pressure.
  • the welding head 2, which will be described later consists of electrodes that can be moved towards each other. Since these electrodes have to be serviced at regular intervals, the welding chamber 1 must be opened forcibly. In order to achieve a clean atmosphere in the welding chamber 1 for the welding after this maintenance work, the welding chamber 1 can be evacuated. The welding chamber is sealed tightly after the service or maintenance work and evacuated The atmospheric gases are extracted and then the welding chamber 1 is optionally filled with inert gas so that it is ready for operation again in the shortest possible time
  • a drying oven 3 and a pre-chamber 4 are pre-built for the welding chamber 1.
  • the welding chamber 1 also has an exit lock chamber 5. It is certainly extremely important with this system. that at least the openings of the welding chamber 1, i.e. the inlet opening from the pre-chamber 4 into the welding chamber 1 and also the opening from the welding chamber 1 into the outlet lock chamber 5, can be closed by means of lock flaps 6, 7.
  • the connection opening from drying oven 3 to prechamber 4 is provided with a connecting lock 9
  • the metal housings provided with the electronic components are dried in the drying oven 3, temporarily stored in the antechamber 4, sealed in the welding chamber 1 and discharged via the exit lock chamber 5.
  • the welding chamber 1 is connected to a gas drying circuit.
  • the welding head 2 has a servo drive 11 for moving the electrode 10.
  • a servo drive 11 for moving the electrode 10.
  • the housing 12 of the welding head 2 is a servo drive 11 for moving the electrode 10.
  • the spindle 14 is provided with a spindle nut 16, which in turn moves the electrode 10 via at least two bolts 17.
  • the bolts 17 have a suspension 19.
  • the suspension 18 can also be a spring assembly
  • the welding head 2 is closed shortly before the welding
  • the metal housing 20 to be welded lies in a corresponding recess in the lower electrodes.
  • the upper electrode 10a has a sealing ring 21 for sealing off the second electrode 10b. After the electrodes 10a, 10b have been closed and before welding, evacuation is carried out; this additional evacuation has brought about a clear improvement in quality.
  • Diagram 4 the sequence of movements in the course of the welding process is shown over time.
  • Diagram a shows the build-up of force during the welding process
  • diagram b the spring travel of the suspension 18
  • diagram c the movement of the electrode 10a
  • diagram d the movement sequence of the servo drive
  • diagram me the summation of the movement sequences or the speed of the overall system.
  • the servo drive is started at maximum speed up to the first point of contact with the element to be welded. Shortly before reaching the touchdown point
  • the electrode is returned to the starting position at maximum speed (diagram e position 34).

Landscapes

  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Resistance Welding (AREA)

Abstract

L'objectif de l'invention est la création d'une installation garantissant une qualité supérieure de fabrication. Selon un des critères de qualité relatifs à de telles installations, on doit pouvoir fermer les boîtiers de façon hermétique, l'intérieur desdits boîtiers devant être absolument exempt d'oxygène et de vapeur d'eau. L'installation selon l'invention se caractérise en ce qu'il est possible de faire de vide dans la chambre de soudage (1) et en ce que la tête de soudage (2) est pourvue d'au moins une électrode pouvant être déplacée au moyen d'un dispositif d'entraînement assisté. Grâce à l'invention, il est pour la première fois possible d'exécuter des travaux d'entretien, tels que le remplacement régulier des électrodes, en un temps le plus court possible. En outre, le dispositif d'entraînement assisté permet, de part ses temps de fermeture courts, l'obtention d'une fréquence élémentaire élevée dans la ligne de production. Ainsi, après les travaux d'entretien ou de maintenance, on ferme la chambre de soudage (1) hermétiquement et on y fait le vide, cette dernière opération prenant en moyenne 15 minutes. Tous les gaz atmosphériques sont aspirés, puis la chambre de soudage (1) est remplie avec un gaz inerte. L'installation est remise à l'état opérationnel en un temps le plus court possible.
PCT/AT1996/000121 1995-07-11 1996-07-11 Installation pour la fermeture automatisee et hermetique de boitiers WO1997002920A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU62930/96A AU6293096A (en) 1995-07-11 1996-07-11 System for automated hermetic sealing of casings
EP96921811A EP0837751A1 (fr) 1995-07-11 1996-07-11 Installation pour la fermeture automatisee et hermetique de boitiers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0117095A AT402617B (de) 1995-07-11 1995-07-11 Anlage zum automatisierten, hermetischen anlage zum automatisierten, hermetischen verschliessen von gehäusen verschliessen von gehäusen
ATA1170/95 1995-07-11

Publications (1)

Publication Number Publication Date
WO1997002920A1 true WO1997002920A1 (fr) 1997-01-30

Family

ID=3508128

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT1996/000121 WO1997002920A1 (fr) 1995-07-11 1996-07-11 Installation pour la fermeture automatisee et hermetique de boitiers

Country Status (4)

Country Link
EP (1) EP0837751A1 (fr)
AT (1) AT402617B (fr)
AU (1) AU6293096A (fr)
WO (1) WO1997002920A1 (fr)

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006123182A2 (fr) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Sulfones de cyclohexyle pour le traitement du cancer
WO2007093827A1 (fr) 2006-02-15 2007-08-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Dérivés de trifluoroéthanone substitués par thiophène et thiazole en tant qu'inhibiteurs d'histone désacétylase (hdac)
WO2008106692A1 (fr) 2007-03-01 2008-09-04 Novartis Vaccines And Diagnostics, Inc. Inhibiteurs de pim kinase et procédés de leur utilisation
WO2008144062A1 (fr) 2007-05-21 2008-11-27 Novartis Ag Inhibiteurs du csf-1r, compositions et procédés d'utilisation
WO2009002495A1 (fr) 2007-06-27 2008-12-31 Merck & Co., Inc. Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase
WO2010114780A1 (fr) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
WO2011046771A1 (fr) 2009-10-14 2011-04-21 Schering Corporation Pipéridines substituées qui accroissent l'activité de p53, et utilisations de ces composés
EP2336120A1 (fr) 2007-01-10 2011-06-22 Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. Combinaisons contenant indazoles à substitution amide utilisés comme inhibiteurs de la poly(ADP-ribose)polymérase (PARP)
WO2011115725A2 (fr) 2010-03-16 2011-09-22 Dana-Farber Cancer Institute, Inc. Composés d'indazole et leurs utilisations
WO2011163330A1 (fr) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
WO2012018754A2 (fr) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian)
WO2012024170A2 (fr) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani)
WO2012027236A1 (fr) 2010-08-23 2012-03-01 Schering Corporation Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
WO2012030685A2 (fr) 2010-09-01 2012-03-08 Schering Corporation Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
WO2012036997A1 (fr) 2010-09-16 2012-03-22 Schering Corporation Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
WO2012058210A1 (fr) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA)
WO2012087772A1 (fr) 2010-12-21 2012-06-28 Schering Corporation Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
WO2012145471A1 (fr) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Inhibiteurs du récepteur du facteur de croissance 1 analogue à l'insuline
WO2013063214A1 (fr) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
WO2013165816A2 (fr) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. Compositions de petit acide nucléique interférent (sina)
EP2698157A1 (fr) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
WO2014052563A2 (fr) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Nouveaux composés inhibiteurs de erk
WO2014085216A1 (fr) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Compositions et procédés pour traiter le cancer
WO2014100065A1 (fr) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Imidazopyridines substituées en tant qu'inhibiteurs de hdm2
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
WO2016020864A1 (fr) 2014-08-06 2016-02-11 Novartis Ag Inhibiteurs de protéine kinase c et leurs procédés d'utilisation
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2018058022A1 (fr) 2016-09-26 2018-03-29 Merck Sharp & Dohme Corp. Anticorps anti-cd27
WO2018071283A1 (fr) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Inhibiteurs de kdm5
WO2018190719A2 (fr) 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anticorps anti-sirp alpha
WO2019094312A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2019094311A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2019152642A1 (fr) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anticorps bispécifiques anti-pd-1/lag3
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2020033284A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2020033282A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2024180169A1 (fr) 2023-03-02 2024-09-06 Carcimun Biotech Gmbh Moyens et procédés de diagnostic du cancer et/ou d'une maladie inflammatoire aiguë

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3190952A (en) * 1963-02-21 1965-06-22 Bitko Sheldon Welded hermetic seal
JPS59147785A (ja) * 1983-02-09 1984-08-24 Origin Electric Co Ltd 抵抗溶接方法
GB2164794A (en) * 1984-09-17 1986-03-26 Lohja Ab Oy Method for encapsulating semiconductor components mounted on a carrier tape

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3190952A (en) * 1963-02-21 1965-06-22 Bitko Sheldon Welded hermetic seal
JPS59147785A (ja) * 1983-02-09 1984-08-24 Origin Electric Co Ltd 抵抗溶接方法
GB2164794A (en) * 1984-09-17 1986-03-26 Lohja Ab Oy Method for encapsulating semiconductor components mounted on a carrier tape

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 8, no. 276 (M - 346)<1713> 18 December 1984 (1984-12-18) *

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006123182A2 (fr) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Sulfones de cyclohexyle pour le traitement du cancer
WO2007093827A1 (fr) 2006-02-15 2007-08-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Dérivés de trifluoroéthanone substitués par thiophène et thiazole en tant qu'inhibiteurs d'histone désacétylase (hdac)
EP2946778A1 (fr) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Procédé de traitement utilisant des inhibiteurs de la synthèse d'acides gras
EP2698157A1 (fr) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
EP2336120A1 (fr) 2007-01-10 2011-06-22 Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. Combinaisons contenant indazoles à substitution amide utilisés comme inhibiteurs de la poly(ADP-ribose)polymérase (PARP)
EP2805945A1 (fr) 2007-01-10 2014-11-26 MSD Italia S.r.l. Indazoles substitués d'amide en tant qu'inhibiteurs PARP de poly(ADP-ribose)polymérase
WO2008106692A1 (fr) 2007-03-01 2008-09-04 Novartis Vaccines And Diagnostics, Inc. Inhibiteurs de pim kinase et procédés de leur utilisation
WO2008144062A1 (fr) 2007-05-21 2008-11-27 Novartis Ag Inhibiteurs du csf-1r, compositions et procédés d'utilisation
EP3103791A1 (fr) 2007-06-27 2016-12-14 Merck Sharp & Dohme Corp. Dérivés de4-carboxybenzylamino utilisés comme inhibiteurs de l'histone désacétylase
WO2009002495A1 (fr) 2007-06-27 2008-12-31 Merck & Co., Inc. Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase
WO2010114780A1 (fr) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
US9505784B2 (en) 2009-06-12 2016-11-29 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
WO2011046771A1 (fr) 2009-10-14 2011-04-21 Schering Corporation Pipéridines substituées qui accroissent l'activité de p53, et utilisations de ces composés
WO2011115725A2 (fr) 2010-03-16 2011-09-22 Dana-Farber Cancer Institute, Inc. Composés d'indazole et leurs utilisations
WO2011163330A1 (fr) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
WO2012018754A2 (fr) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian)
EP3330377A1 (fr) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian)
EP4079856A1 (fr) 2010-08-17 2022-10-26 Sirna Therapeutics, Inc. Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani)
WO2012024170A2 (fr) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani)
WO2012027236A1 (fr) 2010-08-23 2012-03-01 Schering Corporation Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
WO2012030685A2 (fr) 2010-09-01 2012-03-08 Schering Corporation Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
WO2012036997A1 (fr) 2010-09-16 2012-03-22 Schering Corporation Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
WO2012058210A1 (fr) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA)
EP3327125A1 (fr) 2010-10-29 2018-05-30 Sirna Therapeutics, Inc. Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina)
EP3766975A1 (fr) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina)
WO2012087772A1 (fr) 2010-12-21 2012-06-28 Schering Corporation Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
WO2012145471A1 (fr) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Inhibiteurs du récepteur du facteur de croissance 1 analogue à l'insuline
WO2013063214A1 (fr) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
EP3919620A1 (fr) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
WO2013165816A2 (fr) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. Compositions de petit acide nucléique interférent (sina)
WO2014052563A2 (fr) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Nouveaux composés inhibiteurs de erk
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014085216A1 (fr) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Compositions et procédés pour traiter le cancer
WO2014100065A1 (fr) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Imidazopyridines substituées en tant qu'inhibiteurs de hdm2
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
WO2016020864A1 (fr) 2014-08-06 2016-02-11 Novartis Ag Inhibiteurs de protéine kinase c et leurs procédés d'utilisation
EP3514151A1 (fr) 2014-08-06 2019-07-24 Novartis AG Inhibiteurs de protéine kinase c et leurs procédés d'utilisation
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US12098154B2 (en) 2015-03-27 2024-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2018058022A1 (fr) 2016-09-26 2018-03-29 Merck Sharp & Dohme Corp. Anticorps anti-cd27
WO2018071283A1 (fr) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Inhibiteurs de kdm5
WO2018190719A2 (fr) 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anticorps anti-sirp alpha
WO2019094312A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2019094311A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2019152642A1 (fr) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anticorps bispécifiques anti-pd-1/lag3
WO2020033282A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033284A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2024180169A1 (fr) 2023-03-02 2024-09-06 Carcimun Biotech Gmbh Moyens et procédés de diagnostic du cancer et/ou d'une maladie inflammatoire aiguë

Also Published As

Publication number Publication date
AT402617B (de) 1997-07-25
EP0837751A1 (fr) 1998-04-29
AU6293096A (en) 1997-02-10
ATA117095A (de) 1996-11-15

Similar Documents

Publication Publication Date Title
AT402617B (de) Anlage zum automatisierten, hermetischen anlage zum automatisierten, hermetischen verschliessen von gehäusen verschliessen von gehäusen
DE2609115C2 (de) Vakuum-Zerstäubungsvorrichtung
DE2624156C1 (de) Einrichtung zur Behandlung von flachen Werkstücken mit Strömungsitteln
DE3105831C2 (de) Vorrichtung zur Elektronenstrahl-Bearbeitung von Metallwerkstücken
DE3508004A1 (de) Verfahren und vorrichtung zum reinigen von formen
EP0492114A1 (fr) Appareillage de pulvérisation
DE4408947A1 (de) Vakuumbehandlungsanlage und Ventilanordnung
EP0601379A2 (fr) Méthode de montage d&#39;un accumulateur de chaleur de véhicule automobile
DE2628819A1 (de) Herstellung von gasentladungsbildschirmen
DE10048210B4 (de) Vorrichtung und Verfahren zum Einschleusen eines Werkstücks über eine Vorvakuumkammer in eine Hochvakuumkammer und deren Verwendung
DE3343193A1 (de) Gas-wolfram-bogenschweissvorrichtung
DE2263738A1 (de) Zerstaeubungsvorrichtung
EP0639441B1 (fr) Procédé et dispositif de remplissage des cuves de mousse polyuréthane sans CFC
DE3205501A1 (de) Vakuumofen zum entwachsen und sintern von hartmetallen
EP1006211A1 (fr) Procédé et appareil de traitement de substrats par plasma
DE3415012A1 (de) Verfahren und vorrichtung zum kontinuierlichen bearbeiten von substraten mit niederdruck-plasma
EP4358286A1 (fr) Tête de remplissage
DE4405500C2 (de) Einrichtung zur Durchführung elektronenstrahltechnologischer Prozesse im Vakuum
DE2811773C2 (de) Verfahren und Anlage zum Elektronenstrahlschweißen
DE112019007323T5 (de) Ionenanalysator
DE2508337C3 (de) Vakuumgießanlage
WO1989005225A1 (fr) Procede de fabrication de pieces moulees en matiere synthetique et dispositif pour la mise en oeuvre de ce procede
WO2010063436A1 (fr) Dispositif de traitement de pièces sous vide présentant un fond d&#39;enveloppe mobile en rotation par rapport à l&#39;enveloppe
DE3017138C2 (de) Verfahren zum Herstellen eines füllstutzenlosen Balgelements o.dgl. und Vorrichtung zur Durchführung dieses Verfahrens
DE4422751C1 (de) Einrichtung zur Elektronenstrahlbearbeitung

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE FI GE HU IS JP KE KG KP KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996921811

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996921811

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1996921811

Country of ref document: EP